Re-engineering the ant colony optimization for CMP architectures

[EN] The ant colony optimization (ACO) is inspired by the behavior of real ants, and as a bioinspired method, its underlying computation is massively parallel by definition. This paper shows re-engineering strategies to migrate the ACO algorithm applied to the Traveling Salesman Problem to modern Intel-based multi- and many-core architectures in a step-by-step methodology. The paper provides detailed guidelines on how to optimize the algorithm for the intra-node (thread and vector) parallelization, showing the performance scalability along with the number of cores on different Intel architectures, reporting up to 5.5x speedup factor between the Intel Xeon Phi Knights Landing and Intel Xeon v2. Moreover, parallel efficiency is provided for all targeted architectures, finding that core load imbalance, memory bandwidth limitations, and NUMA effects on data placement are some of the key factors limiting performance. Finally, a distributed implementation is also presented, reaching up to 2.96x speedup factor when running the code on 3 nodes over the single-node counterpart version. In the latter case, the parallel efficiency is affected by the synchronization frequency, which also affects the quality of the solution found by the distributed implementation.This work was partially supported by the Fundación Séneca, Agencia de Ciencia y Tecnología de la Región de Murcia under Project 20813/PI/18, and by Spanish Ministry of Science, Innovation and Universities as well as European Commission FEDER funds under Grants TIN2015-66972-C5-3-R, RTI2018-098156-B-C53, TIN2016-78799-P (AEI/FEDER, UE), and RTC-2017-6389-5. We acknowledge the excellent work done by Victor Montesinos while he was doing a research internship supported by the University of Murcia.Cecilia-Canales, JM.; García Carrasco, JM. (2020). Re-engineering the ant colony optimization for CMP architectures. The Journal of Supercomputing (Online). 76(6):4581-4602. https://doi.org/10.1007/s11227-019-02869-8S45814602766Yang XS (2010) Nature-inspired metaheuristic algorithms. Luniver Press, LebanonAkila M, Anusha P, Sindhu M, Selvan Krishnasamy T (2017) Examination of PSO, GA-PSO and ACO algorithms for the design optimization of printed antennas. In: IEEE Applied Electromagnetics Conference (AEMC)Dorigo M, Stützle T (2004) Ant colony optimization. A bradford book. The MIT Press, CambridgeCecilia JM, García JM, Nisbet A, Amos M, Ujaldón M (2013) Enhancing data parallelism for ant colony optimization on GPUs. J Parallel Distrib Comput 73(1):42–51Dawson L, Stewart I (2013) Improving ant colony optimization performance on the GPU using CUDA. In: IEEE Conference on Evolutionary Computation, pp 1901–1908Llanes A, Cecilia JM, Sánchez A, García JM, Amos M, Ujaldón M (2016) Dynamic load balancing on heterogeneous clusters for parallel ant colony optimization. Cluster Comput 19(1):1–11Cecilia JM, Llanes A, Abellán JL, Gómez-Luna J, Chang L, Hwu WW (2018) High-throughput ant colony optimization on graphics processing units. J Parallel Distrib Comput 113:261–274Lloyd H, Amos M (2016) A Highly Parallelized and Vectorized Implementation of Max–Min Ant System on Intel Xeon Phi. In: IEEE computational intelligenceTirado F, Barrientos RJ, González P, Mora M (2017) Efficient exploitation of the Xeon Phi architecture for the ant colony optimization (ACO) metaheuristic. J Supercomput 73(11):5053–5070Montesinos V, García JM (2018) Vectorization strategies for ant colony optimization on intel architectures. Parallel Computing is Everywhere. IOS Press, Amsterdam, pp 400–409Lawler E, Lenstra J, Kan A, Shmoys D (1987) The Traveling salesman problem. Wiley, New YorkMontesinos V (June 2018) Performance analysis of ant colony optimization on intel architectures. Master’s Thesis, University of Murcia (Spain)Lloyd H, Amos M (2017) Analysis of independent roulette selection in parallel ant colony optimization. In: Genetic and Evolutionary Computation Conference, ACM, pp 19–26Dorigo M (1992) Optimization, learning and natural algorithms. Ph.D. Thesis, Politecnico di Milano, ItalyDuran A, Klemm M (2012) The intel many integrated core architecture. In: Internal Conference on High Performance Computing and Simulation (HPCS), pp 365–366The OpenMP API specification for parallel programming. URL: https://www.openmp.org . [Last accessed 14 June 2018]The Message Passing Interface (MPI) standard. URL: http://www.mcs.anl.gov/research/projects/mpi/ . [Last accessed 15 June 2018]Vladimirov A, Asai R (2016) Clustering modes in Knights landing processors: developer’s guide. Colfax international. URL: https://colfaxresearch.com/knl-numa/ . [Last accessed: 16 June 2018]Intel Developer Zone. URL: https://software.intel.com/en-us/modern-code . [Last accessed 02 Oct 2018]Pearce M (2018) What is code modernization? Intel developer zone. URL: http://software.intel.com/en-us/articles/what-is-code-modernization . [Last accessed 15 Feb 2018]Stützle T ACOTSP v1.03. Last accessed 15 Feb 2018. URL: http://iridia.ulb.ac.be/~mdorigo/ACO/downloads/ACOTSP-1.03.tgzReinelt G (1991) TSPLIB—a traveling salesman problem library. ORSA J Comput 3:376–384Crainic TG, Toulouse M (2003) Parallel strategies for meta-heuristics. State-of-the-art handbook in metaheuristics. Kluwer Academic Publishers, Dordrecht, pp 475–513Delévacq A, Delisle P, Gravel M, Krajecki M (2013) Parallel ant colony optimization on graphics processing units. J Parallel Distrib Comput 73(1):52–61Skinderowicz R (2016) The GPU-based parallel ant colony system. J Parallel Distrib Comput 98:48–60Zhou Y, He F, Hou N, Qiu Y (2018) Parallel ant colony optimization on multi-core SIMD CPUs. Future Gener Comput Syst 79:473–487Peake J, Amos M, Yiapanis P, Lloyd H (2018) Vectorized candidate set selection for parallel ant colony optimization. In: Genetic and Evolutionary Computation Conference, ACM, pp 1300–1306Stützle T (1998) Parallelization strategies for ant colony optimization. In: Eiben AE, Bäck T, Schoenauer M, Schwefel HP (eds) Parallel problem solving from nature—PPSN V. PPSN. Lecture Notes in Computer Science, vol 1498. Springer, Berlin, HeidelbergAbdelkafi O, Lepagnot J, Idoumghar L (2014) Multi-level parallelization for hybrid ACO. In: Siarry P, Idoumghar L, Lepagnot J (eds) Swarm Intelligence Based Optimization. ICSIBO 2014. Lecture Notes in Computer Science, vol 8472. Springer, ChamMichel R, Middendorf M (1998) An island model based ant system with lookahead for the shortest super sequence problem. In: Eiben AE, Bäck T, Schoenauer M, Schwefel HP (eds) Parallel problem solving from nature— PPSN V. PPSN. Lecture Notes in Computer Science, vol 1498. Springer, Berlin, HeidelbergChen L, Sun H, Wang S (2008) Parallel implementation of ant colony optimization on MPP. In: International Conference on Machine Learning and CyberneticsLin Y, Cai H, Xiao J, Zhang J (2007) Pseudo parallel ant colony optimization for continuous functions. In: International Conference on Natural Computatio

PTEN Deletion in Adult Mice Induces Hypoinsulinemia With Concomitant Low Glucose Levels

The PI3K/AKT pathway, negatively regulated by PTEN, plays a paramount role in glucose metabolism regulation due to its activation by the insulin receptor signaling pathway. We generated a PTEN-KO mouse to evaluate the systemic effect of the overactivation of the PI3K/AKT pathway in insulin signaling and glucose homeostasis. Our results demonstrate that PTEN-KO mice show very low glucose levels in the fasted state, which poorly respond to glucose and pyruvate administration. Insulinemia decreased without alterations in pancreatic islets. Among the possible reasons, we uncover the deregulation of the expression of proximal tubule glucose transporter and consequent glycosuria. Moreover, we evidence an altered activation of hepatic gluconeogenesis-related genes. In addition, the expression of several genes related to β-oxidation showed a delayed or even absent response to fasting, suggesting that the lack of PTEN not only impairs glucose metabolism but also slows down the use of lipids as a metabolic fuel. We conclude that the inducible full PTEN-KO mice could be a good model to study the metabolic interactions between glycidic and lipidic metabolism in hypoinsulinemic hypoglycemia and that PTEN could be an important mediator in the disease and/or a potential drug target

Lung transplantation from uncontrolled and controlled donation after circulatory death: similar outcomes to brain death donors

Controlled donation after circulatory death donors (cDCD) are becoming a frequent source of lungs grafts worldwide. Conversely, lung transplantations (LTx) from uncontrolled donors (uDCD) are sporadically reported. We aimed to review our institutional experience using both uDCD and cDCD and compare to LTx from brain death donors (DBD). This is a retrospective analysis of all LTx performed between January 2013 and December 2019 in our institution. Donor and recipient characteristics were collected and univariate, multivariate and survival analyses were carried out comparing the three cohorts of donors. A total of 239 (84.7%) LTx were performed from DBD, 29 (10.3%) from cDCD and 14 (5%) from uDCD. There were no statistically significant differences in primary graft dysfunction grade 3 at 72 h, 30- and 90-day mortality, need for extracorporeal membrane oxygenation after procedure, ICU and hospital length of stay, airway complications, CLAD incidence or survival at 1 and 3 years after transplant (DBD: 87.1% and 78.1%; cDCD: 89.7% and 89.7%; uDCD: 85.7% and 85.7% respectively; P = 0.42). Short- and mid-term outcomes are comparable between the three types of donors. These findings may encourage and reinforce all types of donation after circulatory death programmes as a valid and growing source of suitable organs for transplantatio

Clinical Efficacy and Safety of Fanhdi^®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study

Objective: To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods: A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Results: Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions: Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patientsThe author(s) disclosed receipt of the followingfinancial support forthe research, authorship, and/or publication of this article: This workwas supported by Grifols, manufacturer of the pdVWF/FVIII,Fanhdi

Differences in clinical features and mortality in very old unvaccinated patients (≥ 80 years) hospitalized with COVID-19 during the first and successive waves from the multicenter SEMI-COVID-19 Registry (Spain)

Background: Old age is one of the most important risk factors for severe COVID-19. Few studies have analyzed changes in the clinical characteristics and prognosis of COVID-19 among older adults before the availability of vaccines. This work analyzes differences in clinical features and mortality in unvaccinated very old adults during the first and successive COVID-19 waves in Spain. Methods This nationwide, multicenter, retrospective cohort study analyzes unvaccinated patients >= 80 years hospitalized for COVID-19 in 150 Spanish hospitals (SEMI-COVID-19 Registry). Patients were classified according to whether they were admitted in the first wave (March 1-June 30, 2020) or successive waves (July 1-December 31, 2020). The endpoint was all-cause in-hospital mortality, expressed as the case fatality rate (CFR). Results Of the 21,461 patients hospitalized with COVID-19, 5,953 (27.7%) were >= 80 years (mean age [IQR]: 85.6 [82.3-89.2] years). Of them, 4,545 (76.3%) were admitted during the first wave and 1,408 (23.7%) during successive waves. Patients hospitalized in successive waves were older, had a greater Charlson Comorbidity Index and dependency, less cough and fever, and met fewer severity criteria at admission (qSOFA index, PO2/FiO2 ratio, inflammatory parameters). Significant differences were observed in treatments used in the first (greater use of antimalarials, lopinavir, and macrolides) and successive waves (greater use of corticosteroids, tocilizumab and remdesivir). In-hospital complications, especially acute respiratory distress syndrome and pneumonia, were less frequent in patients hospitalized in successive waves, except for heart failure. The CFR was significantly higher in the first wave (44.1% vs. 33.3%; -10.8%; p = 95 years (54.4% vs. 38.5%; -15.9%; p < 0.001). After adjustments to the model, the probability of death was 33% lower in successive waves (OR: 0.67; 95% CI: 0.57-0.79). Conclusions Mortality declined significantly between the first and successive waves in very old unvaccinated patients hospitalized with COVID-19 in Spain. This decline could be explained by a greater availability of hospital resources and more effective treatments as the pandemic progressed, although other factors such as changes in SARS-CoV-2 virulence cannot be ruled out

Gender-Based Differences by Age Range in Patients Hospitalized with COVID-19: A Spanish Observational Cohort Study

There is some evidence that male gender could have a negative impact on the prognosis and severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The aim of the present study was to compare the characteristics of coronavirus disease 2019 (COVID-19) between hospitalized men and women with confirmed SARS-CoV-2 infection. This multicenter, retrospective, observational study is based on the SEMI-COVID-19 Registry. We analyzed the differences between men and women for a wide variety of demographic, clinical, and treatment variables, and the sex distribution of the reported COVID-19 deaths, as well as intensive care unit (ICU) admission by age subgroups. This work analyzed 12,063 patients (56.8% men). The women in our study were older than the men, on average (67.9 vs. 65.7 years; p < 001). Bilateral condensation was more frequent among men than women (31.8% vs. 29.9%; p = 0.007). The men needed non-invasive and invasive mechanical ventilation more frequently (5.6% vs. 3.6%, p < 0.001, and 7.9% vs. 4.8%, p < 0.001, respectively). The most prevalent complication was acute respiratory distress syndrome, with severe cases in 19.9% of men (p < 0.001). In men, intensive care unit admission was more frequent (10% vs. 6.1%; p < 0.001) and the mortality rate was higher (23.1% vs. 18.9%; p < 0.001). Regarding mortality, the differences by gender were statistically significant in the age groups from 55 years to 89 years of age. A multivariate analysis showed that female sex was significantly and independently associated with a lower risk of mortality in our study. Male sex appears to be related to worse progress in COVID-19 patients and is an independent prognostic factor for mortality. In order to fully understand its prognostic impact, other factors associated with sex must be considered

Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)

Altres ajuts: Agustí Barnadas: Honoraria: Pfizer. Consulting or Advisory Role: Pfizer, Novartis, Eli Lilly. Speakers'Bureau: Roche, Pfizer, Novartis, Genomic Health International. Travel, Accommodations, Expenses: Roche, Pfizer; Miguel A. Seguí: Consulting or Advisory Role: Roche, Pfizer, Novartis, Amgen, Eisai, Eli Lilly. Speakers' Bureau: Roche, Pfizer, Amgen. Research Funding: Roche (Inst), Novartis (Inst). Travel, Accommodations, Expenses: Roche, Pfizer, Novartis, Amgen.Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion of standard chemotherapy in patients with early TNBC. Eligible patients were those with operable, node-positive-or node negative with tumor 1 cm or greater-TNBC, with prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation of TNBC status by immunohistochemistry, patients were randomly assigned to either capecitabine or observation. Stratification factors included institution, prior taxane-based therapy, involved axillary lymph nodes, and centrally determined phenotype (basal v nonbasal, according to cytokeratins 5/6 and/or epidermal growth factor receptor positivity by immunohistochemistry). The primary objective was to compare disease-free survival (DFS) between both arms. Eight hundred seventy-six patients were randomly assigned to capecitabine (n = 448) or observation (n = 428). Median age was 49 years, 55.9% were lymph node negative, 73.9% had a basal phenotype, and 67.5% received previous anthracyclines plus taxanes. Median length of follow-up was 7.3 years. DFS was not significantly prolonged with capecitabine versus observation [hazard ratio (HR), 0.82; 95% CI, 0.63 to 1.06; P =.136]. In a preplanned subgroup analysis, nonbasal patients seemed to derive benefit from the addition of capecitabine with a DFS HR of 0.53 versus 0.94 in those with basal phenotype (interaction test P =.0694) and an HR for overall survival of 0.42 versus 1.23 in basal phenotype (interaction test P =.0052). Tolerance of capecitabine was as expected, with 75.2% of patients completing the planned 8 cycles. This study failed to show a statistically significant increase in DFS by adding extended capecitabine to standard chemotherapy in patients with early TNBC. In a preplanned subset analysis, patients with nonbasal phenotype seemed to obtain benefit with capecitabine, although this will require additional validation

Fingerprints as Predictors of Schizophrenia: A Deep Learning Study

Background and hypothesis: The existing developmental bond between fingerprint generation and growth of the central nervous system points to a potential use of fingerprints as risk markers in schizophrenia. However, the high complexity of fingerprints geometrical patterns may require flexible algorithms capable of characterizing such complexity. Study design: Based on an initial sample of scanned fingerprints from 612 patients with a diagnosis of non-affective psychosis and 844 healthy subjects, we have built deep learning classification algorithms based on convolutional neural networks. Previously, the general architecture of the network was chosen from exploratory fittings carried out with an independent fingerprint dataset from the National Institute of Standards and Technology. The network architecture was then applied for building classification algorithms (patients vs controls) based on single fingers and multi-input models. Unbiased estimates of classification accuracy were obtained by applying a 5-fold cross-validation scheme. Study results: The highest level of accuracy from networks based on single fingers was achieved by the right thumb network (weighted validation accuracy = 68%), while the highest accuracy from the multi-input models was attained by the model that simultaneously used images from the left thumb, index and middle fingers (weighted validation accuracy = 70%). Conclusion: Although fitted models were based on data from patients with a well established diagnosis, since fingerprints remain lifelong stable after birth, our results imply that fingerprints may be applied as early predictors of psychosis. Specially, if they are used in high prevalence subpopulations such as those of individuals at high risk for psychosis.This work was supported by several grants funded by the Instituto de Salud Carlos III and the Spanish Ministry of Science and Innovation (co-funded by the European Regional Development Fund/European Social Fund “Investing in your future”): Miguel Servet Research Contract (CPII13/00018 to RS, CPII16/00018 to EP-C, CP20/00072 to MF-V), PFIS Contract (FI19/0352 to MG-R). Research Mobility programme (MV18/00054 to EP-C), Research Projects (PI18/00877 and PI21/00525 to RS). It has also been supported by the Centro de Investigación Biomédica en Red de Salud Mental and the Generalitat de Catalunya: 2014SGR1573 and 2017SGR1365 to EP-C and SLT008/18/00206 to IF-R from the Departament de Salut. The authors have declared that there are no conflicts of interest in relation to the subject of this study.S